Wikipedia

Prodigiosin

Prodigiosin is a red dye produced by many strains of the bacterium Serratia marcescens,[1][2] as well as other Gram-negative, gamma proteobacteria such as Vibrio psychroerythrus and Hahella chejuensis. It is responsible for the pink tint occasionally found in grime that accumulates on porcelain surfaces such as bathtubs, sinks, and toilet bowls. It is in the prodiginine family of compounds which are produced in some Gram-negative gamma proteobacteria, as well as select Gram-positive Actinobacteria (e.g. Streptomyces coelicolor).[3] The name prodigiosin is derived from prodigious (i.e. something marvelous).

Prodigiosin
Names
IUPAC name
4-Methoxy-5-[(Z)-(5-methyl-4-pentyl-2H-pyrrol-2-ylidene)methyl]-1H,1′H-2,2′-bipyrrole
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
MeSH Prodigiosin
UNII
  • InChI=1S/C20H25N3O/c1-4-5-6-8-15-11-16(22-14(15)2)12-19-20(24-3)13-18(23-19)17-9-7-10-21-17/h7,9-13,21,23H,4-6,8H2,1-3H3/b16-12+ checkY
    Key: SZXDNGVQRDTJSD-FOWTUZBSSA-N checkY
  • InChI=1/C20H25N3O/c1-4-5-6-8-15-11-16(22-14(15)2)12-19-20(24-3)13-18(23-19)17-9-7-10-21-17/h7,9-13,21,23H,4-6,8H2,1-3H3/b16-12+
    Key: SZXDNGVQRDTJSD-FOWTUZBSBS
  • CCCCCc3cc(=Cc2[nH]c(c1ccc[nH]1)cc2OC)nc3C
Properties
C20H25N3O
Molar mass 323.440 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

Secondary metabolite

edit

Prodigiosin is a secondary metabolite of Serratia marcescens. Because it is easy to detect, it has been used as a model system to study secondary metabolism. Prodigiosin production has long been known to be enhanced by phosphate limitation. In low phosphate conditions, pigmented strains have been shown to grow to a higher density than unpigmented strains.[4]

Religious function

edit

The ability of pigmented strains of Serratia marcescens to grow on bread has led to a possible explanation of Medieval transubstantiation miracles, in which Eucharistic bread is converted into the Body of Christ. Such miracles led to Pope Urban IV instituting the Feast of Corpus Christi in 1264. This followed celebration of a Mass at Bolsena in 1263, led by a Bohemian priest who had doubts concerning transubstantiation.[3] During the Mass, the eucharist appeared to bleed and each time the priest wiped away the blood, more would appear. This event is celebrated in a fresco in the Pontifical Palace in the Vatican City, painted by Raphael: The Mass at Bolsena.[5]

Biological activity

edit

Prodigiosin received renewed attention[3][6] for its wide range of biological activities, including activities as antimalarial,[7] antifungal,[8] immunosuppressant,[9] and antibiotic agents.[10] It is perhaps best known for its capacity to trigger apoptosis of malignant cancer cells. The exact mechanism of this inhibition is highly complex and not entirely elucidated, but could involve multiple processes, including phosphatase inhibition, copper mediated cleavage of double stranded DNA, or disrupting the pH gradient through transmembrane transport of H+ and Cl- ions.[11] As a result, prodigiosin is a highly promising drug lead, and is currently in preclinical phase study for pancreatic cancer treatment.[12] Prodigiosin has recently been found to have excellent activity against stationary phase Borrelia burgdorferi, the causative agent of Lyme disease.[13]

Production

edit

Biosynthesis

edit
 
Chemical transformations and gene clusters for prodiginine biosynthetic pathways[14]
 
Figure 1: Structure of Prodigiosin 1 highlighting the A, B, and C pyrrole rings

The biosynthesis of prodigiosin[15][16] and related analogs, the prodiginines[3][14] involves the convergent coupling of three pyrrole type rings (labeled A, B, and C in figure 1) from L-proline, L-serine, L-methionine, pyruvate, and 2-octenal.[17]

Ring A is synthesized from L-proline through the nonribosomal peptide synthase (NRPS) pathway (figure 2), wherein the pyrrolidine ring is oxidized, with flavin adenine dinucleotide (FAD+) as the coenzyme to yield pyrrole ring A. In the first step, proline is attached to a peptidyl carrier protein (PCP) called pigG by the action of the enzyme pigI and then the enzyme pigA performs the oxidation.

 

Ring A is then expanded via the polyketide synthase pathway to incorporate L-serine into ring B (figure 3). Ring A fragment is transferred from the peptidyl carrier protein (PCP) to the acyl carrier protein (ACP) by a keto-synthase (KS) domain, followed by transfer to malonyl-ACP via decarboxylative Claisen condensation catalysed by the enzyme pigJ. This fragment is then able to react with the masked carbanion formed from the pyridoxal phosphate (PLP) mediated decarboxylation of L-serine, which cyclizes in a dehydration reaction to yield the second pyrrole ring. This intermediate is then modified by oxidation of the primary alcohol to the aldehyde, catalysed by pigM, and methylation (which incorporates a methyl group from L-methionine onto the alcohol at the 6-position) catalysed by pigF and pigN. This yields the core A-B ring structure ready for further transformations, including to the tambjamines[18] as well as the prodiginines.

 

Ring C is formed from the thiamine pyrophosphate (TPP) mediated decarboxylative addition of pyruvate to 2-octenal, catalysed by pigD. PigE then converts the intermediate to an amine (using an amino-acid and PLP) ready for intramolecular condensation. PigB oxidises the resulting ring using oxygen and FAD+, yielding the pyrrole.

 

Finally, the two pieces are combined by pigC and its cofactor adenosine triphosphate (ATP) in a dehydration reaction which establishes a conjugated system across all three rings and completes the synthesis of prodigiosin.

 

Laboratory

edit

Details of the first total synthesis of prodigiosin were published in 1962, confirming the chemical structure. As with the biosynthesis, the key intermediate was the A-B aldehyde shown in Figure 5.[19] This aldehyde has subsequently been prepared by other methods and used to make prodigiosin and related natural products.[16]

Uses

edit

Potential pharmaceutical uses of prodigiosin, or its use as a dyestuff, have led to studies of its production from Serratia marcescens, possibly after genetic modification.[20]

See also

edit
  • Obatoclax, an experimental drug with related chemical structure

References

edit
  1. ^ Bennett JW, Bentley R (2000). "Seeing red: The story of prodigiosin". Adv Appl Microbiol. Advances in Applied Microbiology. 47: 1–32. doi:10.1016/S0065-2164(00)47000-0. ISBN 9780120026470. PMID 12876793.
  2. ^ Yu, Victor L. (1979). "Serratia marcescens — Historical Perspective and Clinical Review". New England Journal of Medicine. 300 (16): 887–893. doi:10.1056/NEJM197904193001604. PMID 370597.
  3. ^ a b c d Williamson NR, Fineran PC, Gristwood T, Leeper FJ, Salmond GP (2006). "The biosynthesis and regulation of bacterial prodiginines". Nature Reviews Microbiology. 4 (12): 887–899. doi:10.1038/nrmicro1531. PMID 17109029. S2CID 11649828.
  4. ^ M. Todd-Guay and P.H. Demchick. 1995. Role of prodigiosin in phosphate-starved Serratia marcescens. Abstract of the Annual Meeting, American Society for Microbiology.
  5. ^ "The Mass at Bolsena by Raphael". Vatican Museums. Retrieved 2017-08-18.
  6. ^ Williamson NR, Fineran PC, Gristwood T, Chawrai SR, Leeper FJ, Salmond GP (2007). "Anticancer and immunosuppressive properties of bacterial prodiginines". Future Microbiol. 2 (6): 605–618. doi:10.2217/17460913.2.6.605. PMID 18041902.
  7. ^ Castro, A. J. (1967). "Antimalarial Activity of Prodigiosin". Nature. 213 (5079): 903–904. Bibcode:1967Natur.213..903C. doi:10.1038/213903a0. PMID 6030049. S2CID 4221849.
  8. ^ Berg, G. Diversity of antifungal and plant-associated Serratia plymuthica strains. J. Appl. Microbiol. 88, 952–960 (2000).
  9. ^ Magae, J., Miller, M. W., Nagai, K. & Shearer, G. M. Effect of metacycloprodigiosin, an inhibitor of killer T cells on murine skin and heart transplants. J. Antibiot. (Tokyo) 49, 86–90 (1996).
  10. ^ Kataoka, T.; et al. (1995). "Prodigiosin 25-C uncouples vacuolar type H+-ATPase, inhibits vacuolar acidification and affects glycoprotein processing". FEBS Lett. 359 (1): 53–59. doi:10.1016/0014-5793(94)01446-8. PMID 7851530. S2CID 30504320.
  11. ^ Rastogi, S.; et al. (2013). "Synthetic prodigiosenes and the influence of C-ring substitution on DNA cleavage, transmembrane chloride transport and basicity". Org. Biomol. Chem. 11 (23): 3834–3845. doi:10.1039/c3ob40477c. PMID 23640568.
  12. ^ Perez-Tomas, R.; Vinas, M. (2010). "New Insights on the Antitumoral Properties of Prodiginines". Curr. Med. Chem. 17 (21): 2222–2231. doi:10.2174/092986710791331103. PMID 20459382.
  13. ^ Feng, Jie; Shi, Wanliang; Zhang, Shuo; Zhang, Ying (3 June 2015). "Identification of new compounds with high activity against stationary phase Borrelia burgdorferi from the NCI compound collection". Emerging Microbes & Infections. 4 (5): e31–. doi:10.1038/emi.2015.31. PMC 5176177. PMID 26954881.
  14. ^ a b Sakai-Kawada, Francis E.; Ip, Courtney G.; Hagiwara, Kehau A.; Awaya, Jonathan D. (2019). "Biosynthesis and Bioactivity of Prodiginine Analogs in Marine Bacteria, Pseudoalteromonas: A Mini Review". Frontiers in Microbiology. 10: 1715. doi:10.3389/fmicb.2019.01715. PMC 6667630. PMID 31396200.
  15. ^ Walsh, Christopher T.; Garneau-Tsodikova, Sylvie; Howard-Jones, Annaleise R. (2006). "Biological formation of pyrroles: Nature's logic and enzymatic machinery". Natural Product Reports. 23 (4): 517–31. doi:10.1039/B605245M. PMID 16874387.
  16. ^ a b Hu, Dennis X.; Withall, David M.; Challis, Gregory L.; Thomson, Regan J. (2016). "Structure, Chemical Synthesis, and Biosynthesis of Prodiginine Natural Products". Chemical Reviews. 116 (14): 7818–7853. doi:10.1021/acs.chemrev.6b00024. PMC 5555159. PMID 27314508.
  17. ^ R. Caspi (2014-08-14). "Pathway: prodigiosin biosynthesis". MetaCyc Metabolic Pathway Database. Retrieved 2021-04-01.
  18. ^ Brass, Hannah U. C.; Klein, Andreas S.; Nyholt, Silke; Classen, Thomas; Pietruszka, Jörg (2019). "Condensing Enzymes from Pseudoalteromonadaceae for Prodiginine Synthesis". Advanced Synthesis & Catalysis. doi:10.1002/adsc.201900183.
  19. ^ Rapoport, Henry.; Willson, Clyde D. (1962). "The Preparation and Properties of Some Methoxypyrroles". Journal of the American Chemical Society. 84 (4): 630–635. doi:10.1021/ja00863a025.
  20. ^ Yip, Chee-Hoo; Yarkoni, Orr; Ajioka, James; Wan, Kiew-Lian; Nathan, Sheila (2019). "Recent advancements in high-level synthesis of the promising clinical drug, prodigiosin". Applied Microbiology and Biotechnology. 103 (4): 1667–1680. doi:10.1007/s00253-018-09611-z. PMID 30637495. S2CID 58004883.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Prodigiosin&oldid=1249259573"